Download PDF
Osteologie 2013; 22(04): 253-259
DOI: 10.1055/s-0038-1630135
Osteoporosis in men
Schattauer GmbH

The influence of gonadal hormones on skeletal health in men

Sexualhormone und ihre Bedeutung in der Entstehung der männlichen Osteoporose
C. Meier
1   Klinik für Endokrinologie, Diabetologie und Metabolismus, Universitätsspital Basel, Schweiz
,
M. E. Kraenzlin
1   Klinik für Endokrinologie, Diabetologie und Metabolismus, Universitätsspital Basel, Schweiz
› Author Affiliations
Further Information

Publication History

received: 30 August 2013

accepted: 31 August 2013

Publication Date:
30 January 2018 (online)

    Permissions and Reprints

Summary

Osteoporosis in men has only recently begun to receive more attention despite it being estimated that about one third of all osteoporotic fractures occur in men and that the residual lifetime fracture risk in a man aged 60 years may be as high as 30 %. Accrual of bone mass and age-related bone loss in aging healthy men are multifactorial processes involving hormonal, environmental, and genetic factors. This review will summarise the effects of gonadal steroids on bone turnover and bone mass in both, men with over hypogonadism and healthy elderly men with age-related androgen deficiency.

Zusammenfassung

Die Osteoporose bei Männern wird nach wie vor unterschätzt, obwohl etwa ein Drittel aller osteoporotischen Frakturen bei Männern auftreten und das Risiko, bei normaler Lebenserwartung eine Fraktur zu erleiden, bei Männern bis zu 30 % betragen kann. Der Mineralgehaltsaufbau in der Adoleszenz und der nach Erreichen der maximalen Knochenmasse beginnende Knochenmasseverlust im Alter sind multifaktoriell bedingt. Dabei spielen hormonelle und genetische Faktoren sowie Komorbiditäten eine entscheidende Rolle. In dieser Übersichtsarbeit werden die Wirkung gonadaler Hormone auf den Knochenstoffwechsel und die Knochenmasse beim Mann zusammengefasst und am Beispiel des männlichen Hypogonadismus bzw. skelettaler Veränderungen bei altersbedingter Androgendefizienz illustriert.

Keywords

Osteoporosis in men - testosterone - estradiol

Schlüsselwörter

Osteoporose bei Männern - Testosteron - Estradiol
 

  • References

  • 1 Handelsman DJ. Androgen action and pharmacologic uses. In: DeGroot L. ed Endocrinology. Philadelphia: W. B. Saunders; 2001: 2232-2242.
    Google Scholar
  • 2 de Ronde W, Pols HA, van Leeuwen JP, de Jong FH. The importance of oestrogens in males. Clin Endocrinol (Oxf) 2003; 58 (5) 529-542.
    CrossrefPubMedGoogle Scholar
  • 3 Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: results of a meta-analysis. J Clin Epidemiol 1991; 44 (7) 671-684.
    CrossrefPubMedGoogle Scholar
  • 4 Liu PY, Swerdloff RS, Veldhuis J. The rationale, efficacy and safety of androgen therapy in older men: Future research and current practice recommendations. J Clin Endocrinol Metab 2004; 89 (10) 4789-4796.
    CrossrefPubMedGoogle Scholar
  • 5 Ly LP, Handelsman DJ. Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol 2005; 152 (3) 471-478.
    CrossrefPubMedGoogle Scholar
  • 6 Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003; 24 (3) 313-340.
    CrossrefPubMedGoogle Scholar
  • 7 Feldman HA, Longcope C, Derby CA. et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87 (2) 589-598.
    CrossrefPubMedGoogle Scholar
  • 8 Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. Aging Male 2002; 5 (2) 98-102.
    CrossrefPubMedGoogle Scholar
  • 9 Khosla S, Melton 3rd LJ, Atkinson EJ. et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83 (7) 2266-2274.
    PubMedGoogle Scholar
  • 10 Seeman E. Invited Review: Pathogenesis of osteoporosis. J Appl Physiol 2003; 95 (5) 2142-2151.
    CrossrefPubMedGoogle Scholar
  • 11 Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359 (9320) 1841-1850.
    CrossrefPubMedGoogle Scholar
  • 12 Khosla S, Melton 3rd LJ, Riggs BL. Clinical review 144: Estrogen and the male skeleton. J Clin Endocrinol Metab 2002; 87 (4) 1443-1450.
    CrossrefPubMedGoogle Scholar
  • 13 Riggs BL, Khosla S, Melton 3rd LJ. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002; 23 (3) 279-302.
    CrossrefPubMedGoogle Scholar
  • 14 Smith EP, Boyd J, Frank GR. et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331 (16) 1056-1061.
    CrossrefPubMedGoogle Scholar
  • 15 Smith EP, Specker B, Bachrach BE. et al. Impact on bone of an estrogen receptor-alpha gene loss of function mutation. J Clin Endocrinol Metab. 2008 93. (8) 3088-3096. PubMed PMID: 18505767.
    PubMedGoogle Scholar
  • 16 Meier C, Seibel MJ, Handelsman DJ. Testicular dysfunction and bone. In: Orwoll E, Bilezikian J, Vanderschueren D. eds Osteoporosis in men. San Diego: Academic Press; 2010: 179-184.
    Google Scholar
  • 17 Saad F, Adachi JD, Brown JP. et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008; 26 (33) 5465-5476.
    CrossrefPubMedGoogle Scholar
  • 18 Luisetto G, Mastrogiacomo I, Bonanni G. et al. Bone mass and mineral metabolism in Klinefelter's syndrome. Osteoporos Int 1995; 5 (6) 455-461.
    CrossrefPubMedGoogle Scholar
  • 19 Bojesen A, Juul S, Gravholt CH. Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin Endocrinol Metab 2003; 88 (2) 622-626.
    CrossrefPubMedGoogle Scholar
  • 20 Groth KA, Skakkebaek A, Host C. et al. Clinical review: Klinefelter syndrome – a clinical update. J Clin Endocrinol Metab 2013; 98 (1) 20-30.
    CrossrefPubMedGoogle Scholar
  • 21 Aminorroaya A, Kelleher S, Conway AJ. et al. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol 2005; 152 (6) 881-886.
    CrossrefPubMedGoogle Scholar
  • 22 Behre HM, Kliesch S, Leifke E. et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82 (8) 2386-2390.
    CrossrefPubMedGoogle Scholar
  • 23 Vanderschueren D, Vandenput L, Boonen S. et al. Androgens and bone. Endocr Rev 2004; 25 (3) 389-425.
    CrossrefPubMedGoogle Scholar
  • 24 Wang C, Swedloff RS, Iranmanesh A. et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. Testosterone Gel Study Group. J Clin Endocrinol Metab 2000; 85 (8) 2839-2853.
    Google Scholar
  • 25 Wang C, Cunningham G, Dobs A. et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89 (5) 2085-2098.
    CrossrefPubMedGoogle Scholar
  • 26 Wang C, Swerdloff R, Kipnes M. et al. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004; 89 (8) 3821-3829.
    CrossrefPubMedGoogle Scholar
  • 27 Szulc P, Munoz F, Claustrat B. et al. Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J Clin Endocrinol Metab 2001; 86 (1) 192-199.
    PubMedGoogle Scholar
  • 28 Khosla S, Melton 3rd LJ, Atkinson EJ, O'Fallon WM. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 2001; 86 (8) 3555-3561.
    CrossrefPubMedGoogle Scholar
  • 29 Meier C, Liu PY, Handelsman DJ, Seibel MJ. Endocrine regulation of bone turnover in men. Clin Endocrinol (Oxf) 2005; 63 (6) 603-616.
    CrossrefPubMedGoogle Scholar
  • 30 Gennari L, Merlotti D, Martini G. et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab 2003; 88 (11) 5327-5333.
    CrossrefPubMedGoogle Scholar
  • 31 Slemenda CW, Longcope C, Zhou L. et al. Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 1997; 100 (7) 1755-1759.
    PubMedGoogle Scholar
  • 32 Greendale GA, Edelstein S, Barrett Connor. Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 1997; 12 (11) 1833-1843.
    CrossrefPubMedGoogle Scholar
  • 33 Kenny AM, Prestwood KM, Marcello KM, Raisz LG. Determinants of bone density in healthy older men with low testosterone levels. J Gerontol A Biol Sci Med Sci 2000; 55 (9) M492-M497.
    CrossrefPubMedGoogle Scholar
  • 34 Mellstrom D, Johnell O, Ljunggren O. et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006; 21 (4) 529-535.
    CrossrefPubMedGoogle Scholar
  • 35 Goderie-Plomp HW, van der Klift M, de Ronde W. et al. Endogenous sex hormones, sex hormone-binding globulin, and the risk of incident vertebral fractures in elderly men and women: the Rotterdam Study. J Clin Endocrinol Metab 2004; 89 (7) 3261-3269.
    CrossrefPubMedGoogle Scholar
  • 36 Amin S, Zhang Y, Felson DT. et al. Estradiol, testosterone, and the risk for hip fractures in elderly men from the Framingham Study. Am J Med 2006; 119 (5) 426-433.
    CrossrefPubMedGoogle Scholar
  • 37 Bjornerem A, Emaus N, Berntsen GK. et al. Circulating sex steroids, sex hormone-binding globulin, and longitudinal changes in forearm bone mineral density in postmenopausal women and men: the Tromso study. Calcif Tissue Int 2007; 81 (2) 65-72.
    CrossrefPubMedGoogle Scholar
  • 38 Kuchuk NO, van Schoor NM, Pluijm SM. et al. The association of sex hormone levels with quantitative ultrasound, bone mineral density, bone turnover and osteoporotic fractures in older men and women. Clin Endocrinol (Oxf) 2007; 67 (2) 295-303.
    CrossrefPubMedGoogle Scholar
  • 39 Mellstrom D, Vandenput L, Mallmin H. et al. Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 2008; 23 (10) 1552-1560.
    CrossrefPubMedGoogle Scholar
  • 40 Meier C, Kraenzlin ME, Bodmer M. et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008; 168 (8) 820-825.
    CrossrefPubMedGoogle Scholar
  • 41 Spitzer M, Huang G, Basaria S. et al. Risks and benefits of testosterone therapy in older men. Nature reviews Endocrinology 2013; 9 (7) 414-424.
    CrossrefPubMedGoogle Scholar
  • 42 Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75 (4) 1092-1098.
    PubMedGoogle Scholar
  • 43 Snyder PJ, Peachey H, Hannoush P. et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84 (6) 1966-1972.
    PubMedGoogle Scholar
  • 44 Amory JK, Watts NB, Easley KA. et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89 (2) 503-510.
    CrossrefPubMedGoogle Scholar
  • 45 Kenny AM, Prestwood KM, Gruman CA. et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci 2001; 56 (5) M266-M272.
    CrossrefPubMedGoogle Scholar
  • 46 Tracz MJ, Sideras K, Bolona ER. et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab 2006; 91 (6) 2011-2016.
    PubMedGoogle Scholar
  • 47 Wang C, Nieschlag E, Swerdloff R. et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159 (5) 507-514.
    CrossrefPubMedGoogle Scholar
  • 48 Falahati-Nini A, Riggs BL, Atkinson EJ. et al. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 2000; 106 (12) 1553-1560.
    CrossrefPubMedGoogle Scholar
  • 49 Doran PM, Riggs BL, Atkinson EJ, Khosla S. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 2001; 16 (11) 2118-2125.
    CrossrefPubMedGoogle Scholar
  • 50 Meier C, Liu PY, Ly LP. et al. Recombinant human chorionic gonadotropin but not dihydrotestosterone alone stimulates osteoblastic collagen synthesis in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 2004; 89 (6) 3033-3041.
    CrossrefPubMedGoogle Scholar
  • 51 Leder BZ, LeBlanc KM, Schoenfeld DA. et al. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 2003; 88 (1) 204-210.
    CrossrefPubMedGoogle Scholar
  • 52 Pederson L, Kremer M, Judd J. et al. Androgens regulate bone resorption activity of isolated osteoclasts in vitro. Proc Natl Acad Sci U S A 1999; 96 (2) 505-510.
    CrossrefPubMedGoogle Scholar
  • 53 Meier C, Nguyen TV, Handelsman DJ. et al. Endogenous sex hormones and incident fracture risk in older men. Arch Intern Med 2008; 168 (1) 47-54.
    CrossrefPubMedGoogle Scholar